Pradaxa Lawsuits Mount, as Claims in Federal Litigation Exceed 2,400, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Pradaxa lawsuits on behalf of patients who suffered episodes of uncontrollable hemorrhaging, allegedly due to their use of Pradaxa.

Free Case Review
Our Firm continues to hear from patients who were allegedly harmed by Pradaxa on a regular basis. We are not surprised that the number of Pradaxa lawsuit filings continues to grow.

Pradaxa lawsuits ( filed on behalf of patients who allegedly suffered serious episodes of uncontrollable hemorrhaging due to their use of the blood thinner continue to mount in federal court, Bernstein Liebhard LLP reports. According court documents, at least 2,450 complaints have been filed in the U.S. District Court, Southern District of Illinois as of March 28, 2014, where all federally-filed Pradaxa bleeding claims have been consolidated for pretrial proceedings. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“Our Firm continues to hear from patients who were allegedly harmed by Pradaxa on a regular basis. We are not surprised that the number of Pradaxa lawsuit filings continues to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced cerebral hemorrhage, gastrointestinal bleeding, or other episodes of serious internal bleeding due to Pradaxa.

Pradaxa Bleeding Allegations
According to court documents, all of the Pradaxa lawsuits pending in the Southern District of Illinois similarly allege that Boehringer Ingelheim failed to adequately warn patients and doctors about the heightened risk of dangerous internal bleeding related to Pradaxa, and misleadingly touted the blood thinner as being an improvement over warfarin, a medication that has been on the market for decades. The lawsuits point out that while warfarin bleeding can be easily stopped via the administration of vitamin K, there is no readily-available antidote for bleeding that sometimes occurs with Pradaxa.

Pradaxa was brought to market in 2010, and is approved to decrease the risk of strokes in people who suffer from atrial fibrillation. Last month, a report aired by 7 Action News in Detroit asserted that Pradaxa may be the most complained about drug in the U.S. According to the broadcast, the U.S. Food & Drug Administration (FDA) has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S.*

Pradaxa patients who allegedly suffered uncontrollable internal bleeding due to this drug may be entitled to compensation from Boehringer Ingelheim. Find out more about the litigation involving Pradaxa lawsuits at Bernstein Liebhard LLP’s website. Please call 800-511-5092 to schedule a free, no obligation case review.

*, 7 Action News, February 25, 2014

Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website